Item 5. OTHER INFORMATION

Insider Adoption or Termination of Trading Arrangements:

During the quarter ended March 31, 2026, none of the Company’s directors or officers informed it of the adoption, modification or termination of a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as those terms are defined in Regulation S-K, Item 408, except as described in the table below:


Name and Title	Date Adopted	Character of Trading Agreement	Aggregate Number of Shares of Common Stock to be (Sold) Purchased Pursuant to Trading Agreement		Expiration Date
Kathryn W. Kyle	March 9, 2026	Rule 10b5-1 Trading Arrangement	(1,633)	(1)(2)	April 9, 2027	(3)
Executive Vice President, Chief Legal Officer and Corporate Secretary
Bryan T. Vaughn	March 8, 2026	Rule 10b5-1 Trading Arrangement	(2,813)	(1)	May 7, 2027	(3)
Executive Vice President, Diagnostics

(1)The figure presented represents the shares to be sold on the vesting of equity awards and may vary subject to the achievement of certain performance conditions and/or shares to be withheld for tax purposes.

(2)Ms. Kyle’s plan provides for the sale of up to 195 shares of Common Stock previously acquired from an equity award vesting event.

(3)This trading arrangement permits transactions through the completion of all sales on the respective order entry date.

Previous: Item 1A. RISK FACTORS · Next: Item 6. EXHIBITS